Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
145.66
-3.81 (-2.55%)
At close: May 15, 2026, 4:00 PM EDT
145.98
+0.32 (0.22%)
After-hours: May 15, 2026, 7:59 PM EDT
Revolution Medicines Stock Forecast
Stock Price Forecast
According to 21 analysts polled by S&P Global, Revolution Medicines stock has a consensus rating of "Strong Buy" and an average price target of $181.3. The average 1-year stock price forecast is 24.47% higher than the current stock price, while the lowest is $116 (-20.36%) and the highest is $263 (+80.56%).
Price Target: $181.3 (+24.47%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 8 | 8 | 9 | 8 | 8 |
| Buy | 9 | 9 | 9 | 9 | 11 | 11 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 17 | 17 | 18 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $175 → $205 | Strong Buy | Maintains | $175 → $205 | +40.74% | May 7, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $120 → $172 | Buy | Maintains | $120 → $172 | +18.08% | May 7, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $162 → $165 | Buy | Maintains | $162 → $165 | +13.28% | May 7, 2026 |
| Wedbush | Wedbush | Buy Maintains $147 → $165 | Buy | Maintains | $147 → $165 | +13.28% | May 7, 2026 |
| Needham | Needham | Strong Buy Maintains $186 → $183 | Strong Buy | Maintains | $186 → $183 | +25.64% | May 7, 2026 |
Financial Forecast
Revenue This Year
69.54M
Revenue Next Year
471.00M
from 69.54M
Increased by 577.28%
EPS This Year
-7.70
from -5.95
EPS Next Year
-6.08
from -7.70
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 262.5M | 1.1B | ||||||
| Avg | 69.5M | 471.0M | ||||||
| Low | n/a | 137.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 1,430.0% | ||||||
| Avg | - | 577.3% | ||||||
| Low | - | 98.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -6.50 | -1.62 | ||||||
| Avg | -7.70 | -6.08 | ||||||
| Low | -8.21 | -8.17 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.